Spinal release of tumour necrosis factor activates c-Jun N-terminal kinase and mediates inflammation-induced hypersensitivity. by Bas, DB et al.
UC San Diego
UC San Diego Previously Published Works
Title
Spinal release of tumour necrosis factor activates c-Jun N-terminal kinase and mediates 
inflammation-induced hypersensitivity.
Permalink
https://escholarship.org/uc/item/0v91c607
Journal
European journal of pain (London, England), 19(2)
ISSN
1090-3801
Authors
Bas, DB
Abdelmoaty, S
Sandor, K
et al.
Publication Date
2015-02-01
DOI
10.1002/ejp.544
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
ORIGINAL ARTICLE
Spinal release of tumour necrosis factor activates c-Jun
N-terminal kinase and mediates inflammation-induced
hypersensitivity
D.B. Bas1, S. Abdelmoaty1, K. Sandor1, S. Codeluppi2, B. Fitzsimmons3, J. Steinauer3, X.Y. Hua3, T.L. Yaksh3,
C.I. Svensson1
1 Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
2 Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
3 Department of Anesthesiology, University of California San Diego, La Jolla, USA
Correspondence
Camilla I. Svensson
E-mail: camilla.svensson@ki.se
Funding sources
This work was supported by: NIH DA21654
(C.I.S.), NS16541 (T.L.Y.), Swedish Research
Council (C.I.S.) and the Swedish Association
for Strategic Research (C.I.S.), Marie Curie
International Reintegration grant (C.I.S.).
Conflicts of interest
The authors declare no conflict of interest.
Accepted for publication
3 May 2014
doi:10.1002/ejp.544
Abstract
Background: Mounting evidence points to individual contributions of
tumour necrosis factor-alpha (TNF) and the c-Jun N-terminal kinase (JNK)
pathway to the induction and maintenance of various pain states. Here we
explore the role of spinal TNF and JNK in carrageenan-induced
hypersensitivity. As links between TNF and JNK have been demonstrated
in vitro, we investigated if TNF regulates spinal JNK activity in vivo.
Methods: TNF levels in lumbar cerebrospinal fluid (CSF) were measured
by enzyme-linked immunosorbent assay, spinal TNF gene expression by
real-time polymerase chain reaction and TNF protein expression, JNK and
c-Jun phosphorylation by western blotting. The role of spinal TNF and JNK
in inflammation-induced mechanical and thermal hypersensitivity was
assessed by injecting the TNF inhibitor etanercept and the JNK inhibitors
SP600125 and JIP-1 intrathecally (i.t.). TNF-mediated regulation of JNK
activity was examined by assessing the effect of i.t. etanercept on
inflammation-induced spinal JNK activity.
Results: TNF levels were increased in CSF and spinal cord following
carrageenan-induced inflammation. While JNK phosphorylation followed
the same temporal pattern as TNF, c-jun was only activated at later time
points. Intrathecal injection of TNF and JNK inhibitors attenuated
carrageenan-induced mechanical and thermal hypersensitivity. TNF
stimulation induced JNK phosphorylation in cultured spinal astrocytes and
blocking the spinal actions of TNF in vivo by i.t. injection of etanercept
reduced inflammation-induced spinal JNK activity.
Conclusions: Here we show that spinal JNK activity is dependent on TNF
and that both TNF and the JNK signalling pathways modulate pain-like
behaviour induced by peripheral inflammation.
1. Introduction
Tumour necrosis factor (TNF) is an important pro-
inflammatory cytokine in the initiation and perpetu-
ation of inflammatory responses. It is also a critical
factor in pathological pain states (Wagner and Myers,
1996; Woolf et al., 1997; Vogel et al., 2006) and
mounting evidence points to that TNF induces and
maintains not only peripheral but also spinal sensiti-
zation (Kawasaki et al., 2008; Youn et al., 2008). For
instance, intrathecal (i.t.) TNF induces both thermal
and mechanical hypersensitivity (Kwon et al., 2005;
Kawasaki et al., 2008; Gao et al., 2009). Moreover,
increased gene and/or protein expression levels of
spinal TNF have been reported in different pain
models (Bao et al., 2001; Hao et al., 2007; Cao et al.,
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2010) and blockage of spinal TNF actions attenuates
pain-like behaviour (Svensson et al., 2005; Choi et al.,
2010; Christianson et al., 2011). It has been shown
that spinal TNF can contribute to persistent pain states
by activating mitogen activating protein kinases
(MAPK) such as p38 and c-Jun N-terminal kinase
(JNK; Boyle et al., 2006; Gao et al., 2010).
The JNK has three isoforms, JNK1, JNK2 and JNK3;
all forms are expressed in the central nervous system.
Spinal JNK1 and JNK2 are critical for the development
and maintenance of chronic pain states (Zhuang et al.,
2006; Gao and Ji, 2008; Wang et al., 2012). Activation
of the JNK signalling pathway in experimental models
of pain is further supported by the observation that
c-Jun, one of the main JNK substrates, is activated in
the spinal cord subsequent to peripheral inflammation
and spinal nerve ligation (Gao and Ji, 2008; Gao et al.,
2010). Intrathecal administration of the JNK inhibi-
tors SP600125 and D-JNK-1 attenuates pain-like
behaviour (Obata et al., 2004; Gao et al., 2010; Wang
et al., 2012), indicating that JNK is an important regu-
lator of pain transmission.
As we have previously found that i.t. injection of the
TNF inhibitor etanercept attenuates mechanical
hypersensitivity in the carrageenan model (Choi et al.,
2010), the first aim of this study was to explore if
peripheral inflammation drives spinal synthesis and
release of TNF. Secondly, in order to examine the role
of spinal JNK activation in inflammatory hypersensi-
tivity, we tested if the inhibition of spinal JNK pre-
vents carrageenan-induced pain-like behaviour and if
inflammation-induced activation of spinal JNK is
mediated by TNF. Although a link between TNF and
JNK activation has been demonstrated in in vitro
studies (Pollock et al., 2002; Gao et al., 2009, 2010;
Guma and Firestein, 2012), this has not been hitherto
characterized in an in vivo inflammatory pain model.
Our studies show that spinal JNK activity is dependent
on TNF and that both spinal TNF and JNK are involved
in the hyperalgesia phenotype associated with periph-
eral inflammation.
2. Methods
2.1 Animals
Experiments were carried out according to protocols
approved by the Institutional Animal Care Committee of the
University of California, San Diego (UCSD) and the local
Swedish ethical committee for animal experiments (Stock-
holms Norra Djurförsöksetiska Nämnd) and complied with
ethical guidelines of the International Association for the
Study of Pain (Zimmermann, 1983). Male Holzman
Sprague-Dawley rats (300–350 g, Harlan Laboratories, India-
napolis, IN, USA and the Netherlands) were housed indi-
vidually in micro isolator filter cages (UCSD) and open cage
system (Karolinska Institutet) in a temperature-controlled
room (∼23 °C) and maintained on a 12-h light/dark cycle
with free access to food and water.
Each animal was only subjected to one condition.
2.2 Induction of inflammation and
behavioural analysis
To induce a state of local inflammation, λ-carrageenan
(Sigma Aldrich, St. Louis, MO, USA, 100 μL of 2% solution
(w/v) in saline) was injected subcutaneously into the plantar
surface of the left hind paw of a rat under brief isoflurane
anaesthesia. Animals were habituated to the testing environ-
ment prior to baseline tests. To assess thermal hypersensitiv-
ity, a modified Hargreaves type device was employed (Dirig
et al., 1997). Rats were placed individually in Plexiglas
cubicles with glass surface and after habituation a radiant
heat stimulus was applied to each paw and the latency
defined as the time (seconds) required for the paw to show
a brisk withdrawal. Etanercept was injected i.t. 60 min,
SP600125 and JIP-1 15 min prior to carrageenan injection
(time = 0). The data were also presented as hyperalgesic
index, a calculation that defines the magnitude of
carrageenan-induced sensitization. It represents the area
between the extrapolated baseline and the time-response
curve after carrageenan injection. Increasing values indicate
increasing hypersensitivity.
For assessment of mechanical hypersensitivity, another set
of animals was used. Rats were placed in individual Plexiglas
compartments with wire mesh bottom and after acclimati-
zation, von Frey filaments (0.41–15.2 g, Stoelting, Wood
Dale, IL, USA) were applied perpendicularly to the mid hind
paw and held for 4–6 s. A positive response was noted if the
paw was sharply withdrawn. The 50% probability of with-
What’s already known about this topic?
• Spinal tumour necrosis factor is involved in
inflammation- (CFA) and nerve injury-induced
pain.
• The c-Jun N-terminal kinase (JNK) is activated
in the spinal astrocytes in models of inflamma-
tory (CFA) and neuropathic pain.
What does this study add?
• Spinal TNF is important in carrageenan-induced
hypersensitivity.
• JNK is activated in the spinal cord with a similar
temporal profile as the TNF release and JNK inhi-
bition prevents the onset of carrageenan-induced
hypersensitivity.
• Spinal TNF regulates JNK activity in vivo.
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drawal threshold was determined by Dixon’s up-down
method (Chaplan et al., 1994). Etanercept, JIP-1 and
SP600125 were injected with the same pretreatment times as
listed above. Data were also presented as hyperalgesic index.
2.3 Intrathecal injections and drugs
All drugs were delivered intrathecally in 10 μL vehicle fol-
lowed by 10 μL saline flush. The JNK inhibitor SP600125
(3.3 and 33 μg, Sigma Aldrich) was dissolved in 5% Tween-
80, 20% dimethyl sulfoxide (DMSO) in saline, while the
JIP-1 amide fragment 53–63 (0.3–30 μg, Sigma Aldrich) and
the neutralizing anti-TNF binding protein etanercept (30 and
100 μg, Pfizer, New York, NY, USA) were dissolved in saline.
To allow delivery, chronic lumbar i.t. catheters, single-lumen
polyethylene (OD 0.36 mm, 8.5 cm in length) from the cis-
terna were implanted under isoflurane anaesthesia as
described previously (Yaksh and Rudy, 1976).
2.4 Cerebrospinal fluid (CSF) collection
CSF was collected 1, 2, 4 and 18 h after carrageenan injec-
tion by using micropipettes (0.8–1.1 × 100 mm, KIMAX-51,
Kimble Chase, Vineland, NJ, USA). Isoflurane-anaesthetized
rats were placed in sternal recumbency and a midline skin
incision was made posterior to a length of 3 cm. The muscles
were bluntly dissected and retracted to expose the interspi-
nous space at L4/L5 and the interspinous ligament and L5
spinous process were carefully removed. The L4 spinous
process was elevated and tissue from the dura carefully
removed in order to eliminate blood pooling at the site of
collection. The pulled microcapillary tube was introduced
into the i.t. space and 40–50 μL of CSF was collected. The
CSF was centrifuged to remove cells and the supernatant was
immediately frozen. For soluble form of TNF analysis, 25 μL
of CSF diluted with buffer (1:1) used per well and the
enzyme-linked immunosorbent assay performed according
to the manufacturer’s instructions (R & D Systems, Minne-
apolis, MN, USA).
2.5 Western blot analysis
Under isoflurane anaesthesia ipsilateral lumbar spinal cords
(L1-L6) were removed at 1, 2, 4, 8, 12 and 18 h after carra-
geenan injection. Flash frozen spinal cords were homog-
enized in lysis buffer. The proteins were separated using
NuPAGE 4–12% Bis-Tris gel electrophoresis and 3-
morpholin-4-ylpropane-1-sulfonic acid (MOPS) or 2-(N-
Morpholino)ethanesulfonic acid hydrate (MES) running
buffer (Invitrogen, Gran Island, NY, USA) and transferred to
nitrocellulose membranes (Invitrogen). After blocking non-
specific binding sites the blots were incubated with primary
antibodies against TNF (rabbit, 1:1000, cat No ab66579,
Abcam, Cambridge, UK), phosphorylated JNK (p-JNK,
mouse, 1:1000, cat No 9255, clone G9, Cell Signaling,
Boston, MA, USA), phosphorylated c-Jun (p-c-Jun, rabbit,
1:1000, cat No 9261 and 9164, Cell Signaling), total JNK
(t-JNK, rabbit, 1:2000, cat No 9525, Cell Signaling), total
c-Jun (t-c-Jun, rabbit, cat No 9162) and β-actin (mouse,
1:100000, cat No A2228, clone AC-74, Sigma Aldrich) and
then with horseradish peroxidase-labeled secondary anti-
bodies. Immunopositive bands were detected with chemilu-
minescent reagents and X-Ray film (Kodak, Rochester, NY,
USA). Immunopositive bands were normalized against
β-actin for the respective band and the data expressed as
levels relative to the naïve controls (% of control) within the
same membrane. Signal intensity was measured using Quan-
tity One (BioRad, Hercules, CA, USA). A separated group
was used to detect the effect of TNF inhibition on JNK phos-
phorylation. The ipsilateral lumbar spinal cord sections (L1-
L6) were removed 1 h after etanercept or vehicle (saline)
pretreatment. Relative levels of p-JNK and tot JNK were
assessed as described above.
2.6 Quantitative real-time polymerase chain
reaction (PCR)
Under isoflurane anaesthesia, ipsilateral lumbar spinal cords
(L1-L6) were removed at 1, 2, 4, 8, 12 and 18 h after carra-
geenan injection. Flash frozen spinal cords were extracted
with TRIzol (Invitrogen) according to the manufacturer’s
protocol. The RNAwas reverse transcribed to complementary
DNA (cDNA) and quantitative real-time PCR (GeneAmp7000
Sequence Detection system, Applied Biosystems, Foster City,
CA,USA)was performedwithhydrolysis probes, both accord-
ing to the manufacturer’s instructions, to determine the rela-
tive mRNA levels. Pre-developed specific primers were used
to detect Tnf (Rn99999017_m1) and the reference geneHprt1
(Rn01527838_g1). Data were normalized to Hprt1 mRNA
levels and presented as relative gene expression.
2.7 Statistical analysis
Western blot, qPCR and behavioural data were expressed as
mean ± standard error of the mean (SEM). Western blot,
qPCR and all behavioural hyperalgesic index data except
data showing JIP-1 effect on mechanical hypersensitivity
(Student’s t-test was used) were analysed by one-way analy-
sis of variance (ANOVA) followed by Bonferroni post hoc
test. For all of the behavioural time course analysis, two-way
repeated measures ANOVA was used, followed by Bonfer-
roni post hoc test for correction of multiple comparisons. The
criterion for significance was set as p-values < 0.05.
3. Results
3.1 TNF levels are increased in the CSF and the
spinal cord after carrageenan-induced
peripheral inflammation
We examined if carrageenan-induced inflammation
leads to elevated TNF protein levels in CSF. While TNF
TNF and JNK-mediated inflammatory pain D.B. Bas et al.
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protein levels were not detected in naïve rats (n = 5),
its levels reached detection limit 1 h post-injection of
carrageenan (6.7 ± 4.7 pg/mL; n = 6), and in compari-
son to those levels, a significant increase of TNF was
found in CSF sampled 2 (41.1 ± 16.9 pg/mL; n = 5)
and 4 (32 ± 6.7 pg/mL; n = 6) h after induction of
inflammation (p < 0.05; Fig. 1A). In order to deter-
mine if mRNA and protein levels in the spinal cord
also changed in response to the peripheral inflamma-
tion, L1-L6 spinal cords were collected at different
time points after the carrageenan injection. Tnf mRNA
levels were increased 10-fold 8 h after carrageenan
injection compared with naïve rats (p < 0.05; Fig. 1B).
No difference in relative expression levels of the
housekeeping gene (Hprt1) was observed between the
different time points after injection of carrageenan
(data not shown). TNF protein levels in the spinal cord
were also increased 8 h after carrageenan injection
compared with naïve rats (0 h: 100 ± 15.6%, n = 6;
8 h: 364.7 ± 71.5%, n = 6; p < 0.05), and remained
significantly higher than in control tissues at the 12
and 18 h time points (12 h: 329.7 ± 41.1%, n = 6;
18 h: 493.1 ± 98.4%, n = 3; p < 0.05; Fig. 1C).
3.2 Inhibition of TNF reduces
carrageenan-induced thermal and mechanical
hypersensitivity
As we found that both mRNA and protein levels of
TNF were increased in the spinal cord and TNF was
detected in CSF after induction of peripheral inflam-
mation the soluble TNF receptor etanercept was used
to determine the role of TNF in carrageenan-induced
thermal and mechanical hypersensitivity. Etanercept
(30 and 100 μg) or the vehicle (saline, n = 5–6) was
injected i.t. 1 h before carrageenan injection. While
the 30 μg, i.t. dose did not change withdrawal laten-
cies at any time points (n = 6; p > 0.05; Fig. 2A), it
reduced mechanical thresholds at 60 and 120 min
time points (n = 6; p < 0.05; Fig. 2C). The related
hyperalgesic indices showed that there was no change
in thermal hypersensitivity (p > 0.05; Fig. 2B), but sig-
nificant decrease in mechanical hypersensitivity
(p < 0.05; Fig. 2D). The withdrawal latencies were
longer at 120 and 150 min time points (n = 6; p < 0.05;
▶
Figure 1 Carrageenan-induced peripheral inflammation increases TNF
levels in the spinal cord. Bar graphs displaying (A) TNF levels in CSF (pg/
mL) and (B) mRNA levels presented as relative expression units (REU) and
(C) TNF protein expression as % of control in the lumbar ipsilateral spinal
cord 1, 2, 4, 8, 12 and 18 h after carrageenan injection to the paw, com-
pared with naïve (0 h time point) rats. Representative western blot images
showing TNF and β-actin (loading control) immunopositive bands from
spinal cord homogenates over time after carrageenan injection. Recom-
binant soluble TNF (rTNF) was used as positive control. All data are pre-
sented as mean ± SEM, *p < 0.05; **p < 0.01; ***p < 0.001, versus naive
controls.
D.B. Bas et al. TNF and JNK-mediated inflammatory pain
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Fig. 2A) and the mechanical thresholds were higher at
60, 120 and 150 min time points in the 100 μg, i.t.
etanercept group compared with the vehicle treated
group (n = 7; p < 0.05; Fig. 2C). The related hyperal-
gesic indices showed that 100 μg, i.t. etanercept
delayed the onset of both thermal and mechanical
hypersensitivity (p < 0.05; Fig. 2B and D). No changes
in withdrawal latencies or mechanical thresholds were
observed in the control (without carrageenan injec-
tion) group (n = 6; p > 0.05) (Fig. 2) and contralateral
sides (data not shown).
3.3 Levels of phosphorylated JNK and c-Jun are
increased in spinal cord after
carrageenan-induced inflammation
To investigate if JNK1, JNK2 and the downstream
substrate c-Jun are activated after carrageenan injec-
tion, L1-L6 spinal cords were harvested at different
time points. Three bands were detected with the
p-JNK antibody whereof the lowest was considered
non-specific based on the molecular weight (approxi-
mately 40 kDa) and signal intensities for bands corre-
sponding to 46 kDa (p-JNK1) and 54 kDa (p-JNK2)
levels were quantified. The p-JNK1 signal was very
strong compared with p-JNK2; therefore, the mem-
branes were subjected to a shorter and a longer expo-
sure for assessment of p-JNK1 and p-JNK2,
respectively. p-JNK1 and p-JNK2 levels were signifi-
cantly increased 1, 8, 12 h after carrageenan injection
compared with basal phosphorylation levels of
JNK1/2 (p-JNK1 0 h: 100 ± 9.4%, n = 11; 1 h:
340.4 ± 40%, n = 11; 8 h: 387.7 ± 99.3%, n = 10;
12 h: 572.5 ± 89.2%, n = 6; p < 0.05; p-JNK2 0 h:
100 ± 11.1%, n = 11; 1 h: 282.2 ± 22.3%, n = 11; 8 h:
226.4 ± 45.6%, n = 10; 12 h: 241.3 ± 33.4%, n = 6;
p < 0.05) (Fig. 3A and B). The levels of total JNK1/2
were not changed in the spinal cord subsequent to the
induction of peripheral inflammation (data not
shown). The p-c-Jun levels were increased signifi-
cantly only 12 h after injection compared with basal
phosphorylation levels of c-Jun (0 h: 100 ± 5.2%,
n = 6; 12 h: 300.2 ± 41.8%, n = 4; p < 0.05; Fig. 3C).
The levels of total c-Jun were not changed after
carrageenan-induced peripheral inflammation (data
not shown).
3.4 JNK inhibitors attenuate
carrageenan-induced thermal and mechanical
hypersensitivity
To test the role of spinal JNK in carrageenan-induced
thermal and mechanical hypersensitivity two different
JNK inhibitors, SP600125 (3.3 and 33 μg, i.t.) and
JNK-interacting protein-1 (JIP-1) (0.3–30 μg, i.t.)
were used. Inhibitors and vehicles [5% Tween-80,
20% DMSO in saline (n = 8) and saline (n = 6–7),
respectively] were injected i.t. 15 min before carra-
geenan injection. 3.3 μg, i.t. SP600125 at 90 and
120 min time points (n = 8; p < 0.05) and 33 μg, i.t.
Figure 2 Intrathecal etanercept attenuates
carrageenan-induced thermal and mechanical
hypersensitivity. Graphs showing the effect of
etanercept (30 and 100 μg) injected i.t. 1 h
before carrageenan injection on (A) thermal
withdrawal latencies and (C) mechanical with-
drawal thresholds over time compared with
the i.t. vehicle (saline)-injected group. (B and D)
Bar graphs showing the related hyperalgesic
indeces calculated for the 0–240 min time
period after carrageenan injection. Control
group represent naïve rats without carra-
geenan injection. All data are presented as
mean ± SEM, *p < 0.05; **p < 0.01;
***p < 0.001, versus vehicle controls.
TNF and JNK-mediated inflammatory pain D.B. Bas et al.
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dose at 90, 120, 150 and 180 min time points (n = 9;
p < 0.05) attenuated carrageenan-induced thermal
hypersensitivity (Fig. 4A). The related hyperalgesic
indeces showed that both doses attenuated
carrageenan-induced thermal hypersensitivity
(p < 0.05; Fig. 4A and B). However, we failed to show
any antinociceptive effect on carrageenan-induced
mechanical hypersensitivity with the same doses of
SP600125 (data not shown). To examine if a higher
dose of SP600125 (66 μg, i.t.) has effect on mechanical
hypersensitivity it was injected in a volume of 20 μL
(due to solubility issues at doses higher than 3.3 μg,
i.t.). Unfortunately the 20 μL volume of vehicle had
antinociceptive effects (data not shown) interfering
with the assay and therefore, a second JNK inhibitor,
JIP-1 was included in this study. While i.t. injection of
0.3 μg of JIP-1 attenuated carrageenan-induced
thermal hypersensitivity only at 90 min time point
(n = 4; p < 0.05), 3 μg, i.t. JIP-1 at 60, 90, 120,
150 min time points (n = 6; p < 0.05) and 30 μg, i.t.
JIP-1 at 60, 90, 120 min time points (n = 6; p < 0.05)
increased withdrawal latencies (Fig. 5A). The related
hyperalgesic indeces showed that 3 and 30 μg
(p < 0.05), but not the 0.3 μg (p > 0.05), i.t. JIP-1
reduced the thermal hypersensitivity (Fig. 5B). To test
if JIP-1 also has effect on mechanical hypersensitivity,
the highest dose (30 μg, i.t.) was injected. While we
could not find any statistically difference at any time
point in JIP-1-treated group compared with the
vehicle-treated group (n = 8; p > 0.05; Fig. 5C), the
related hyperalgesic indeces showed that there was a
significant reversal of the carrageenan-induced
mechanical hypersensitivity (p < 0.05; Fig. 5D). No
changes in withdrawal latencies or mechanical thresh-
olds were observed in the control group (without car-
rageenan injection) and contralateral sides (data not
shown).
3.5 Inhibition of TNF reduces increased
phosphorylated levels of JNK after
carrageenan injection
To determine if TNF drives spinal JNK activation after
carrageenan injection, etanercept (100 μg, i.t.) was
Figure 3 Carrageenan-induced peripheral inflammation increases
JNK1/2 and c-Jun activity in the spinal cord. Bar graphs showing percent
(%) change of (A) p-JNK1, (B) p-JNK2 and (C) p-c-Jun in the lumbar ipsilateral
spinal cord 1, 2, 4, 8, 12 and 18 h after carrageenan injection compared
with naïve (0 h time point) rats. Representative western blot images
showing p-JNK1/2, p-c-Jun, total JNK1/2 (t-JNK1/2), total c-Jun (t-c-Jun) and
β-actin (loading control) immunopositive bands from spinal cord homoge-
nates over time after carrageenan injection. All data are presented as
mean ± SEM, **p < 0.01; ***p < 0.001, versus naive controls.
◀
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applied 15 min before the injection of carrageenan.
L1-L6 spinal cords were removed 1 h (peak phospho-
rylation time of JNK) after etanercept pretreatment
and JNK activation was evaluated. The increased
levels of p-JNK1 and p-JNK2 were significantly inhib-
ited by etanercept pretreatment (p-JNK1 control:
100 ± 10.3%, n = 8, carrageenan + vehicle: 294.6 ±
35%, n = 8, carrageenan + etanercept: 142.8 ± 16.5%,
n = 8, p < 0.05; p-JNK2 control: 100 ± 16.1%, n = 8,
carrageenan + vehicle: 271.5 ± 32%, n = 8, carra-
geenan + etanercept: 144.7 ± 29%, n = 8; p < 0.05;
Fig. 6A and B). Total levels of JNK1 and JNK2 were
not changed in any of the groups (data not shown).
4. Discussion and conclusions
In the current study, we show that induction of
peripheral inflammation leads to an increased spinal
gene and protein expression and release of TNF, as
well as activation of JNK in the spinal cord.
Inflammation-induced mechanical and thermal
hypersensitivity were reduced by preventing the
actions of spinal TNF and by inhibiting signalling
through the JNK pathway. This is in line with accu-
mulating evidence that JNK is activated in astrocytes
in response to cytokine stimulation and that JNK acti-
vation is one important intracellular event in the
development of neurological disorders following
injury or disease (Fernandes et al., 2007; Gao et al.,
2009; Zhang et al., 2013).
TNF is a membrane-bound cytokine (mTNF) that is
cleaved by TNF-alpha-converting enzyme to release
the 17 kDa soluble form of TNF (sTNF). TNF is released
by many immune cells, including macrophages and
glial cells and both forms are biologically active and
exert their actions by binding to TNF receptor 1 and 2.
Figure 4 Intrathecal injection of the JNK inhibi-
tor SP600125 attenuates carrageenan-induced
thermal hypersensitivity. (A) Graphs depicting
the effect of SP600125 (3.3 and 33 μg, i.t.),
injected i.t. 15 min before carrageenan injec-
tion on thermal paw withdrawal latencies over
time compared with i.t. vehicle (5% Tween-80,
20% DMSO in saline) injected group. (B) Bar
graphs showing the hyperalgesic index calcu-
lated for the 0–240 min time period after carra-
geenan injection. All data are presented as
mean ± SEM, *p < 0.05; **p < 0.01;
***p < 0.001, versus vehicle controls.
Figure 5 Intrathecal injection of the JNK inhibi-
tor JIP-1 attenuates carrageenan-induced
thermal and mechanical hypersensitivity.
Graphs showing effects of JIP-1 (0.3–30 μg) or
vehicle (saline)-injected i.t. 15 min before carra-
geenan injection on (A) thermal withdrawal
latencies and (C) mechanical withdrawal
thresholds. (B and D) Bar graphs showing the
related hyperalgesic indeces for the 0–240 min
time period after carrageenan injection. All
data are presented as mean ± SEM, *p < 0.05;
**p < 0.01; ***p < 0.001, versus vehicle
controls.
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Our findings are in parallel with earlier reports
showing TNF in CSF (Bianchi et al., 2007) and
elevated gene and protein expressions of TNF and its
role in mechanical and thermal hypersensitivity in
inflammatory pain states (Cunha et al., 1992; Woolf
et al., 1997; Raghavendra et al., 2004; Christianson
et al., 2011). The fact that we could detect TNF in
cell-free (centrifuged) CSF and observed a TNF immu-
noreactive band at approximately 17 kDa by western
blotting of spinal cord homogenates suggests that TNF
is cleaved from cellular membranes in response to a
peripheral inflammation. This is in contrast to previ-
ous work showing that mTNF but not sTNF levels
were significantly increased in the spinal cord after
formalin injection (Zhou et al., 2008). Interestingly, in
the same study, direct exposure of cultured microglia
to a potent inflammatory stimulus resulted in
increased mTNF levels followed by increase in released
sTNF. Thus, it is possible that carrageenan-induced
inflammation, which is more pronounced and lasts
longer than the formalin-induced reaction, activates
proteases that cleave TNF from cellular membranes in
the spinal cord, releasing TNF that is detectable in CSF
prior to increases of Tnf mRNA in the spinal cord
tissue. One alternative explanation for the early
increase of TNF protein levels in CSF is that produc-
tion of TNF at the site of inflammation is redistributed
to CSF. However, as recent findings have shown that
carrageenan-induced paw inflammation does not lead
to elevated plasma levels of TNF (Loram et al., 2007)
or increased blood-spinal cord barrier permeability
(Xanthos et al., 2012), it is not likely that the elevated
spinal TNF levels observed in the current study is the
result of transport of TNF from the periphery to the
spinal cord.
In order to block the actions of spinal TNF, we
injected etanercept intrathecally. Etanercept consists
of two extracellular domains of the human 75 kD
(p75) TNF receptor linked by the constant Fc portion
of human immunoglobulin. This decoy receptor binds
TNF and prevents it from acting on membrane-bound
receptors (Hareoko and Bykerk, 2007). We found that
etanercept prevented both carrageenan-induced
mechanical and thermal hypersensitivity, which is in
agreement with previous works (Inglis et al., 2005;
Boettger et al., 2010; Choi et al., 2010; Christianson
et al., 2010, 2011). Although the exact actions by
which TNF is involved in nociception at the spinal
level remains to be delineated, there are some possible
mechanisms. In the spinal cord, TNF receptors are
expressed on neurons, astrocytes and microglia
(Gruber-Schoffnegger et al., 2013), thus TNF can act
both in a paracrine and autocrine fashion. Once
released, it is thought that TNF facilitates glutamater-
gic synaptic transmission between C fibres and lamina
II neurons (Kawasaki et al., 2008; Zhang and
Dougherty, 2011; Zhang et al., 2011) by binding to
neuronally expressed TNF receptors (Ohtori et al.,
2004; Xu et al., 2006; Zhang and Dougherty, 2011;
Gruber-Schoffnegger et al., 2013). TNF drives neu-
ronal excitability by decreasing inhibitory synaptic
transmission in the spinal dorsal horn (Kawasaki
Figure 6 Intrathecal injection of TNF antagonist etanercept reduces
carrageenan-induced spinal JNK1/2 activation. Bar graphs depicting
percent (%) change of (A) p-JNK1 and (B) p-JNK2 in the lumbar ipsilateral
spinal cord 1 h after carrageenan injection in the presence of i.t. etaner-
cept (100 μg), compared with vehicle (saline) injected control rats. Repre-
sentative western blot images showing immunopositive bands from
spinal cord homogenates for p-JNK1/2, total JNK1/2 (t-JNK1/2) and β-actin
(loading control). All data are presented as mean ± SEM, **p < 0.01;
***p < 0.001, versus vehicle controls.
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et al., 2008; Zhang and Dougherty, 2011),
up-regulating TRPV1 channels in spinal cord (Boettger
et al., 2010) and modulating α-amino-3-hydroxy-5-
methyl-4-isoxazole proprionic acid receptor trafficking
(Choi et al., 2010). Noteworthy, recent work suggests
that the induction of hyperalgesia by TNF is not a
direct neuronal effect but is mediated indirectly via
activation of spinal glial cells and subsequent release of
other neuronally active factors (Gruber-Schoffnegger
et al., 2013).
Despite similar levels of JNK1 and JNK2 proteins in
the spinal cord, we found more pronounced phospho-
rylation of JNK1 than JNK2, both at baselines and
after induction of inflammation. Consistently, the acti-
vation of both JNK1 and JNK2 with a stronger activa-
tion of JNK1 has been shown in the spinal cord after
complete Freund’s adjuvant (CFA) induced inflamma-
tion. Moreover, in the same study, JNK1 modulated
spinal pain signalling to a greater extent than JNK2
(Gao et al., 2010). Of note, in our studies JNK1 and
JNK2 were both activated in a biphasic fashion, fol-
lowing the same temporal pattern of the TNF increase
in CSF. A link between TNF and JNK activation has
been established in earlier work demonstrating that i.t.
TNF leads to spinal activation of JNK (Gao et al.,
2010). In our study, i.t. etanercept injected prior to
induction of inflammation prevented activation of
JNK at the early time point, providing further support
for that TNF receptor activation drives signalling
through the JNK pathway in the spinal cord. Although
we did not assess the antinociceptive actions of etan-
ercept or the effect of TNF blockage on JNK activity at
the later time points, the matching time profile
between the second wave of TNF release and JNK
activation may suggest that these factors are linked
and involved not only in induction of hypersensitivity
but also at later time points. However, further studies
are warranted to explore this causal relationship in
detail. Interestingly, c-Jun, one of the major down-
stream substrates of JNK, was only activated at later
time points suggesting that JNK couples to different
intracellular signalling pathways at different phases of
inflammatory pain.
By immunohistochemistry, we were unable to show
the cellular localization of activated JNK in the spinal
cord. However, earlier works have showed that JNK is
activated in spinal astrocytes, but not in neurons and
microglia in spinal nerve ligation and CFA models
(Gao et al., 2009, 2010). After stimulation with TNF,
rapid activation of both JNK1 and JNK2 was found
demonstrating that phosphorylation of JNK in astro-
cytes is feasible, in support with other studies showing
that astrocytes respond to TNF by MAPK activation
and release of IL-1β, MCP-1, MMP (Guo et al., 2007;
Gao et al., 2009; Guma and Firestein, 2012). It is
important to note however that JNK activation was
detected in spinal neurons in a bone cancer model
(Wang et al., 2012). Even though localization of JNK
activation may be model dependent, we cannot rule
out that JNK was not activated in neurons in the
current study.
Overexpression of JIP-1 deactivates the JNK
pathway and JIP-1 has a higher JNK specificity than
SP600125 (Heo et al., 2004), the second JNK inhibi-
tor that was used in this study. We have previously
found that i.t. JIP-1 attenuated antibody-induced
hypersensitivity in mice (Bas et al., 2012) and here
we show that it also attenuates carrageenan-induced
mechanical and thermal hypersensitivity. Although
the DMSO-containing vehicle of SP600125 interfered
with assessment of mechanical hypersensitivity, it
was effective on carrageenan-induced thermal hyper-
sensitivity. Previously, it has been shown that i.t.
SP600125 has predominant effect on thermal hyper-
sensitivity (Doya et al., 2005; Daulhac et al., 2006;
Cao et al., 2007; Ikeda et al., 2012), and given the
modest effect of JIP-1 on mechanical hypersensitiv-
ity, it is possible that spinal JNK is to a greater
extent involved in thermal than mechanical
hypersensitivity.
In conclusion, our results emphasize that blocking
spinal TNF inhibits both pain-like behaviour and the
increased levels of phosphorylated JNK1 and JNK2
subsequent to carrageenan injection. Previous studies
demonstrating a link between TNF and JNK pathway
have been performed in vitro in astrocytes (Gao et al.,
2009, 2010), synovial fibroblasts and chondrocytes
(Guma and Firestein, 2012), as well as on sensory
neurons (Pollock et al., 2002). To our knowledge, our
work is the first to show TNF-dependent activation of
spinal JNK after peripheral inflammation in vivo. TNF
and signalling pathways downstream of TNF receptor
such as JNK represent potential targets for pain relief.
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